Satellos Establishes Scientific Advisory Board to Explore the Biology of Regeneration in Aging and Neuroscience
Key Highlights
- ➤Satellos (MSLE) forms Scientific Advisory Board spanning regeneration, aging and neuroscience
- ➤Forazapadin advances in two Phase 2 Duchenne muscular dystrophy trials
- ➤FDA cleared an IND for forazapadin’s facioscapulohumeral muscular dystrophy evaluation
- ➤Board will advise on stem cell biology, molecular signaling and disease pathology
Expert Statements
Michael Rudnicki, Co-founder and Chief Discovery Officer of Satellos Bioscience
“Much of my scientific career has been devoted to understanding how cellular polarity governs stem cell function and tissue regeneration.”
Michael Rudnicki, Co-founder and Chief Discovery Officer of Satellos Bioscience
“We are only beginning to appreciate how these fundamental biological processes may influence aging, neurodegeneration and other conditions beyond muscle disease.”
Michael Rudnicki, Co-founder and Chief Discovery Officer of Satellos Bioscience
“I am thrilled to welcome this remarkable group of scientists to our SAB and look forward to exploring new scientific questions that could deepen our understanding of regenerative biology.”
Phil Lambert, Chief Scientific Officer of Satellos Bioscience
“We are honored to bring together this exceptional group of scientists to serve on Satellos’ Scientific Advisory Board.”
Phil Lambert, Chief Scientific Officer of Satellos Bioscience
“The SAB will help deepen our understanding of how cellular polarity influences tissue maintenance, regeneration and disease across multiple biological systems.”
Phil Lambert, Chief Scientific Officer of Satellos Bioscience
“Its collective expertise will broaden our scientific perspective as we explore aging and neuroscience and continue advancing our understanding of regenerative biology.”
TORONTO, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage company developing potentially life-improving medicines to treat degenerative muscle diseases, today announced the formation of a Scientific Advisory Board (SAB) comprised of internationally recognized leaders in stem cell biology, regenerative medicine, neuroscience and small molecule chemistry who will help guide the company's long-term scientific exploration of regeneration, aging and neurodegenerative biology.
“Much of my scientific career has been devoted to understanding how cellular polarity governs stem cell function and tissue regeneration,” said Michael Rudnicki, OC, FRS, co-founder and chief discovery officer. “We are only beginning to appreciate how these fundamental biological processes may influence aging, neurodegeneration and other conditions beyond muscle disease. I am thrilled to welcome this remarkable group of scientists to our SAB and look forward to exploring new scientific questions that could deepen our understanding of regenerative biology.”
Get started
Create a free account to read the full story.